Trials / Conditions / Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

11 registered clinical trials studyying Metastatic Castrate Resistant Prostate Cancer (mCRPC) — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCR NCT07214961	ARTBIO Inc.	Phase 1
Not Yet Recruiting	Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metas NCT07090369	Peter MacCallum Cancer Centre, Australia	Phase 1
Recruiting	Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) NCT06943495	Jean-Mathieu Beauregard	Phase 1
Recruiting	Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer NCT07002320	Institute of Cancer Research, United Kingdom	Phase 1 / Phase 2
Recruiting	A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who W NCT06551324	Pfizer	Phase 3
Recruiting	Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Unde NCT06720532	Hannah Schaefer	—
Recruiting	TmPSMA-02 in mCRPC NCT06046040	University of Pennsylvania	Phase 1
Active Not Recruiting	RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pa NCT04597125	Bayer	Phase 4
Completed	The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC NCT03899467	Suzhou Kintor Pharmaceutical Inc,	Phase 2
Completed	Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer NCT02826772	Suzhou Kintor Pharmaceutical Inc,	Phase 1
Completed	Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. NCT01692262	AstraZeneca	Phase 1